UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
PharmacoEconomics, ISSN 1170-7690, 8/2012, Volume 30, Issue 8, pp. 661 - 679
Quality of Life Research | Health Economics | Health Administration | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | Economics | Social Sciences | Life Sciences & Biomedicine | Health Care Sciences & Services | Pharmacology & Pharmacy | Business & Economics | Health Policy & Services | Science & Technology | Outcome Assessment (Health Care) - methods | Quality-Adjusted Life Years | New York | Prospective Studies | Cross-Sectional Studies | Humans | Child, Preschool | Child Development Disorders, Pervasive - physiopathology | Male | Arkansas | Child Development Disorders, Pervasive - drug therapy | Data Collection - methods | Child Development Disorders, Pervasive - economics | Adolescent | Quality of Life | Female | Retrospective Studies | Child | Asperger-syndrome; Autistic-disorder; Children; Pervasive-child-development-disorders; Quality-adjusted-life-years; Quality-of-life; Quality-of-life-rating-scales; Utility-measurement. | Care and treatment | Autistic children | Medical economics | Analysis | Quality of life
Journal Article
The European journal of health economics, ISSN 1618-7598, 2019, Volume 20, Issue 2, pp. 217 - 232
Health Economics | Economic Policy | I180 | Public Health | Health outcomes | Health reform | Public Finance | Health Care Management | Outcome-based payment models | Payment models in healthcare | Healthcare costs | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | Quality of care | Economics | Social Sciences | Life Sciences & Biomedicine | Business & Economics | Health Care Sciences & Services | Health Policy & Services | Science & Technology | Fee-for-Service Plans - statistics & numerical data | Humans | Quality Indicators, Health Care | Quality of Health Care - statistics & numerical data | Quality of Health Care - economics | Treatment Outcome | Patient Acceptance of Health Care - statistics & numerical data | Fee-for-Service Plans - economics | Reimbursement, Incentive | Diagnosis-Related Groups - statistics & numerical data | Health Care Costs | Quality Improvement | Diagnosis-Related Groups - economics | Analysis | Health care reform | Medical care | Models | Economic incentives | Health aspects | Medical care, Cost of | Quality management | Costs | Health care expenditures | Health economics | Clinical outcomes | Original Paper
Journal Article
PharmacoEconomics, ISSN 1170-7690, 4/2019, Volume 37, Issue 4, pp. 541 - 551
Quality of Life Research | Health Economics | Health Administration | Public Health | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | Economics | Social Sciences | Life Sciences & Biomedicine | Health Care Sciences & Services | Pharmacology & Pharmacy | Business & Economics | Health Policy & Services | Science & Technology | Severity of Illness Index | Humans | Middle Aged | Parents | Child, Preschool | Male | Autism Spectrum Disorder - psychology | Young Adult | Cost-Benefit Analysis | Adolescent | Quality of Life | Adult | Female | Child Health | Child | Caregivers | Autism | Pediatrics | Parents & parenting | Internet access | Mental disorders | Childrens health | Pharmacoeconomics | Families & family life | Cost analysis | Quality of life | Children & youth | Original
Journal Article
PharmacoEconomics, ISSN 1170-7690, 2008, Volume 26, Issue 5, pp. 363 - 370
Outcomes research | Patient preference | Quality of life | Quality of Life Research | Health Economics | Health Administration | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | Economics | Social Sciences | Life Sciences & Biomedicine | Health Care Sciences & Services | Pharmacology & Pharmacy | Business & Economics | Health Policy & Services | Science & Technology | Biological and medical sciences | Medical sciences | General pharmacology | Clinical trial. Drug monitoring | Pharmacology. Drug treatments | Treatment Outcome | Clinical Trials as Topic - legislation & jurisprudence | Reproducibility of Results | Patients | Humans | Outcomes-research; Patient-preference; Quality-of-life | Qualitative research | Medical equipment | Medical research | Research & development--R&D | Clinical trials | Clinical outcomes | Guidelines | Studies | Health economics | Economic theory | Critical path | Pharmaceutical industry | Health technology assessment
Journal Article
The European journal of health economics, ISSN 1618-7598, 12/2019, Volume 20, Issue 9, pp. 1303 - 1315
Health Economics | Economic Policy | Public Health | J33 compensation packages | National health insurance | Public Finance | Diabetes mellitus | Physician practice | Systematic review | Health Care Management | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | H51 government expenditures and health | Pay-for-performance | I11 analysis of health care markets | Economics | Social Sciences | Life Sciences & Biomedicine | Business & Economics | Health Care Sciences & Services | Health Policy & Services | Science & Technology | Single-Payer System | Diabetes Mellitus - therapy | Humans | Quality of Health Care - economics | Female | Male | Treatment Outcome | Practice Patterns, Physicians | Physicians, Primary Care | Reimbursement, Incentive | Studies | Business metrics | Health economics | Pay for performance | Cost analysis | Index Medicus
Journal Article
2014, Directions in development : human development, ISBN 9781464802973, 75
Universal Coverage | Health Expenditures | Health Policy | Health Services Accessibility | Healthcare Financing | Economic Development | Medicare | HEALTH CARE WORKERS | LABOR MARKETS | FINANCIAL RISK PROTECTION | PHYSICIANS | CITIZENSHIP | HEALTH SECTOR | HEALTH ECONOMICS | TECHNICAL CAPACITIES | HUMAN DEVELOPMENT | EFFECTIVE POLICIES | ECONOMIC GROWTH | ACCESS TO SERVICES | INJURIES | OUTPATIENT SERVICES | PRIVATE SECTOR | MEDICAL SUPPLIES | HEALTH SYSTEMS | HUMAN RESOURCES | HEALTH WORKERS | HEALTH SERVICES | HEALTH INSURANCE PROGRAM | MALARIA | URBAN AREAS | INCOME COUNTRIES | MORTALITY | HEALTH CARE PROVISION | PATIENTS | HEALTH SERVICE DELIVERY | TUBERCULOSIS | HEALTH CARE INFRASTRUCTURE | HOSPITALS | CAPITAL INVESTMENTS | POLICY PROCESS | RESOURCE CONSTRAINTS | DECISION MAKING | HEALTH CARE FACILITIES | HEALTH SYSTEMS IN TRANSITION | HEALTH POLICY | NATIONAL PRIORITY | HEALTHCARE | DEMOCRACY | FEE-FOR-SERVICE SYSTEM | AGING | HEALTH INVESTMENTS | INFORMATION SYSTEM | CLINICS | NATIONAL HEALTH SERVICE | HEALTH EXPENDITURES | COMMUNITY HEALTH | PRIMARY HEALTH CARE | HEALTH OUTCOMES | FINANCING HEALTH CARE | POPULAR SUPPORT | MEDICINES | CLINICIANS | HOLISTIC APPROACH | PUBLIC AFFAIRS | PATIENT SATISFACTION | HEALTH CARE PROVIDERS | FEE-FOR-SERVICE | HEALTH INTERVENTIONS | SOCIAL SUPPORT | FINANCIAL RISKS | PHARMACOECONOMICS | ENROLLEES | QUALITY SERVICES | NATIONAL POLICY | HEALTH ORGANIZATION | HEALTH SYSTEM | LABOR MARKET | NATIONAL POLICY AGENDA | SOCIAL HEALTH INSURANCE | COMMUNICABLE DISEASES | HEALTH STATUS | UNIVERSAL ACCESS | POCKET PAYMENTS | HEALTH INSURANCE SYSTEM | WAR | ILLNESS | INCOME GROUPS | SOCIAL INSURANCE | EXPENDITURES | HEALTH RISKS | HEALTH PURCHASER | NATIONAL HEALTH INSURANCE | PROGRESS | DOCTORS | CITIZEN | COST SHARING | MOLECULAR BIOLOGY | WORLD HEALTH ORGANIZATION | HEALTH CARE EXPENDITURES | INSURANCE SYSTEMS | REIMBURSEMENT RATES | SUSTAINABLE DEVELOPMENT | HEALTH FINANCE | HEALTH SPECIALIST | HEALTH SERVICE | ACUTE CARE | FAMILY PLANNING | INTEGRATION | POOR HEALTH | HEALTH CARE | DEMAND FOR HEALTH | HEALTH CARE ACCESS | INFORMAL SECTOR | GOVERNMENT LEADERSHIP | IMPLICATIONS FOR HEALTH | NATIONAL HEALTH | HOSPITAL SECTOR | GROSS DOMESTIC PRODUCT | INFORMAL SECTOR WORKERS | SUSTAINABLE GROWTH | CITIZENS | MEDICAL FACILITIES | MEDICAL SCHOOL | NURSES | HEALTH INSURANCE SCHEME | REHABILITATION | PUBLIC HEALTH PROGRAMS | POLITICAL LEADERSHIP | PRIVATE HEALTH INSURANCE | EMPLOYMENT | MIDWIVES | WORKERS | CAPITATION | QUALITY CARE | DELIVERY SYSTEM | HEALTH CARE REFORM | HEALTH WORKFORCE | MINISTRY OF HEALTH | MEDICAL ASSOCIATIONS | NUTRITION | POLITICAL SUPPORT | POLICY GOALS | FEE-FOR-SERVICE PAYMENT | PUBLIC HEALTH | HEALTH COVERAGE | HEALTH INSURANCE PLANS | FEE-FOR-SERVICE PAYMENT SYSTEMS | HOSPITAL STAFF | POLICY PROCESSES | PHARMACEUTICAL COMPANIES | PUBLIC SPENDING | WORKING CONDITIONS | HEALTH REFORMS | INCOME | PROFESSIONAL ASSOCIATIONS | DRUGS | INSURANCE COVERAGE | HEALTH CARE PROFESSIONALS | POCKET PAYMENTS FOR HEALTH CARE | FINANCIAL RESOURCES | HIV/AIDS | CAPITATION PAYMENTS | VULNERABLE POPULATIONS | DIRECT COSTS | HEALTH CARE REFORMS | ELDERLY | HEALTH POLICIES | FINANCIAL PROTECTION | PRIMARY CARE | LEGAL STATUS | PATIENT | TECHNICAL ASSISTANCE | WORK ENVIRONMENT | FINANCING POLICIES | PUBLIC SECTOR | CAPACITY BUILDING | FEE SCHEDULE | SOCIAL MOVEMENTS | HEALTH SYSTEM PERFORMANCE | DEMAND FOR HEALTH SERVICES | HEALTH PROFESSIONALS | HEALTH EXTENSION | POPULATION GROUPS | POLICY DECISIONS | ACCESS TO HEALTH CARE | LIFE EXPECTANCY | LIVING CONDITIONS | DIAGNOSIS | HEALTH FINANCING | HEALTH CARE PROVIDER | LOW-INCOME COUNTRIES | HEALTH FINANCING SYSTEM | RISK GROUPS | NATIONAL POLICIES | HEALTH REFORM | HEALTH EXPENDITURE | SOCIAL SECURITY | HOSPITAL MANAGEMENT | DELIVERY SYSTEMS | INEQUITIES | CITIES | CONTRIBUTION RATES | PROVIDER PAYMENT | HEALTH FACILITIES | NATIONAL INSURANCE SYSTEMS | DIET | HEALTH SPENDING | HEALTH PLANS | LONG-TERM CARE | GOVERNMENT AGENCIES | PALLIATIVE CARE | FINANCIAL RISK | CATASTROPHIC HEALTH SPENDING | INFANT MORTALITY | HEALTH AFFAIRS | AGING POPULATIONS | POLITICAL CHANGE | HEALTH CARE COSTS
eBook
PharmacoEconomics, ISSN 1170-7690, 3/2017, Volume 35, Issue 3, pp. 375 - 396
Quality of Life Research | Health Economics | Health Administration | Public Health | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | Economics | Social Sciences | Life Sciences & Biomedicine | Health Care Sciences & Services | Pharmacology & Pharmacy | Business & Economics | Health Policy & Services | Science & Technology | Outcome Assessment (Health Care) - methods | Guidelines as Topic | Reproducibility of Results | Cost-Benefit Analysis | Humans | Diabetes Mellitus, Type 2 - therapy | Diabetes Mellitus, Type 2 - economics | Clinical Trials as Topic | Models, Economic | Type 2 diabetes | Economic aspects | Clinical trials | Usage | Patient outcomes | Consortia | Studies | Validity | Accuracy | Hyperglycemia | Simulation | Decision making | Mortality | Pharmacoeconomics | Diabetes | Cost analysis
Journal Article
PharmacoEconomics, ISSN 1170-7690, 3/2017, Volume 35, Issue 3, pp. 319 - 329
Quality of Life Research | Health Economics | Health Administration | Public Health | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | Economics | Social Sciences | Life Sciences & Biomedicine | Health Care Sciences & Services | Pharmacology & Pharmacy | Business & Economics | Health Policy & Services | Science & Technology | Quality-Adjusted Life Years | Hypoglycemic Agents - economics | Glycated Hemoglobin A - metabolism | Humans | Risk Factors | Diabetes Mellitus, Type 2 - economics | Linear Models | Models, Economic | Blood Glucose - drug effects | Hypoglycemic Agents - administration & dosage | Computer Simulation | Cost-Benefit Analysis | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Care and treatment | Usage | Patient outcomes | Analysis | Glycosylated hemoglobin | Risk factors | Quality of life | Studies | Intervention | Life expectancy | Simulation | Systematic review | Diabetes | Cost analysis | Insulin | Systematic Review
Journal Article